ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
ProQR Therapeutics N.V.NASDAQ: PRQR
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of €309K (cash outflow) fell 38.2% year over year, ahead of the -102.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 47.5% from the prior quarter. Over 3 fiscal years it compounded at -61.5% a year.
Context
- Financing cash flow amounted to 11.5% of revenue in FY2025, down 360.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -38.2% holds above the trailing-twelve-month pace of -102.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (1.76M) EUR
- Year-over-year change
- -102.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.76M) | -102.5% |
| FY2024 | 2024-12-31 | 70.28M | +3189.1% |
| FY2023 | 2023-12-31 | (2.28M) | +92.6% |
| FY2022 | 2022-12-31 | (30.89M) | -122.6% |
| FY2021 | 2021-12-31 | 136.83M | — |
Financing Cash Flow vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -102.3% is the 10th highest of 11, against a peer median of -47.0%.
- Financing cash flow amounts to 12.2% of revenue for PRQR, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $250.31M USD | +66.3% | +271.0% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M USD | +11.1% | — | — |
| LTM Mar 2026 | $51.55M USD | +779.8% | +38.7% | — | |
| LTM Mar 2026 | $41.91M USD | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $37.29M USD | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $2.36M USD | +59.4% | — | 1.1% | |
| LTM Mar 2026 | $1.8M USD | -109.8% | — | 4.0% | |
| LTM Mar 2026 | €1.63M EUR | -102.3% | -61.5% | 12.2% | |
| LTM Mar 2026 | $637K USD | -99.4% | +22.8% | 11.1% | |
| FY2025 | A$525.12K AUD | -100.6% | — | 10.4% | |
| LTM Mar 2026 | $95.27K USD | -100.2% | +17.8% | 19.1% | |
| Peer median (excluding PRQR) | — | -47.0% | +77.9% | 10.8% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (60.8M) | (64.2M) | (27.74M) | (27.76M) | (40.52M) |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| Deferred Income Tax | 117K | 96K | (78K) | (197K) | 0 |
| Stock-Based Compensation | 6.22M | 2.87M | 3.11M | 2.54M | 0 |
| Change in Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Other Non-Cash Items | 1.11M | (4.8M) | (5.21M) | (474K) | 3.94M |
| Operating Cash Flow | (26.01M) | (68.51M) | 21.55M | (36.39M) | (50.71M) |
| Capital Expenditures | (484K) | (708K) | (1.37M) | (1.42M) | (979.75K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (17M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 17M | 0 |
| Other Investing Activities | 59K | 6K | 5.65M | (2.66M) | 0 |
| Investing Cash Flow | (425K) | (702K) | 4.28M | (4.07M) | (979.74K) |
| Debt Repayment | 26.84M | (45.05M) | (2.63M) | (1.58M) | (1.91M) |
| Common Stock Issued | 108.48M | 14.12M | 0 | 71.64M | 66.28K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | 34K | 354K | 223K | 75.19K |
| Financing Cash Flow | 136.83M | (30.89M) | (2.28M) | 70.28M | (1.76M) |
| Effect of Forex Changes | 1.29M | 7.35M | 599K | 673K | 14.15M |
| Net Change in Cash | 111.69M | (92.75M) | 24.15M | 30.48M | (39.3M) |
| Free Cash Flow | (26.5M) | (69.22M) | 20.18M | (37.81M) | (51.69M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.